Victoza, belongs to the GLP-1 family of diabetes medications, which also includes Byetta, marketed by Eli Lilly & Co. and Amylin Pharmaceuticals Inc. Both drugs help control blood sugar by increasing insulin production, slowing the body's absorption of sugar.
Novo's drug would enjoy an advantage over Byetta because it requires one injection per day, instead of two.
The company said it expects Victoza, which has been approved in Japan and Europe, to be on the U.S. market within weeks.
via abcnews.go.com
No comments:
Post a Comment